Breakfast Industry Symposium:
What is the true utility of genomic testing in Early Breast Cancer?
A closer look at intrinsic subtyping and Prosigna
Supported by Veracyte
Thursday, September 12, 2024
07:30-08:30
HALL A
Light refreshments will be served prior to the session from 7:00
| Chairperson | Lesley Fallowfield, Sussex, UK |
| 07:30-07:50 | The development of and clinical utility of PAM50 and intrinsic subtyping, and a comparison of the available technologies Matthew J. Ellis, Houston, TX, USA |
| 07:50-08:10 | How will the OPTIMA trial answer many of the outstanding questions around the utility of genomic testing? What effect will the implementation of PREDICT 3 have on the use of GEP testing? Stuart McIntosh, Belfast, UK |
| 08:10-08:30 | How well do healthcare professionals and patients understand the information provided by genomic test reports? Lesley Fallowfield, Sussex, UK |